%0 Journal Article
%A Breitkreutz, Iris
%A Becker, Natalia
%A Benner, Axel
%A Kosely, Florentina
%A Heining, Christoph
%A Hillengass, Jens
%A Egerer, Gerlinde
%A Ho, Anthony D
%A Goldschmidt, Hartmut
%A Raab, Marc-Steffen
%T Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function.
%J Hematological oncology
%V 34
%N 4
%@ 0278-0232
%C New York, NY [u.a.]
%I Wiley Interscience
%M DKFZ-2017-01682
%P 200 - 207
%D 2016
%X Therapeutic options in heavily pretreated relapsed/refractory multiple myeloma patients are often very limited because of impaired bone marrow function. Bendamustine is effective in multiple myeloma and has a favourable toxicity profile. We hypothesized that dose-intensified bendamustine (180 mg/m(2) , day 1 and 2) followed by autologous blood stem cell support (ASCS) would improve bone marrow function with low post-transplant toxicity in patients with severely impaired haematopoiesis. We analyzed 28 consecutive myeloma patients, with a median of three prior lines of therapy (range 2-7), who had relapsed from the last treatment with very limited bone marrow function and were therefore ineligible for conventional chemotherapy, novel agents or trial enrolment. Dose-intensified bendamustine with ASCS improved haematopoiesis as reflected by increased platelet counts (median 40/nl vs 94/nl, p = 0.0004) and white blood cell counts (3.0/nl vs 4.8/nl, p = 0.02) at day +100. The median time until engraftment of platelets (>50/nl) was 11 days (0-24 days) and of white cell counts (>1.0/nl) 0 days (0-24 days). At least, a minimal response was achieved in 36
%K Bendamustine Hydrochloride (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:25784529
%R 10.1002/hon.2199
%U https://inrepo02.dkfz.de/record/125556